fingolimod / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fingolimod / Generic mfg.
PARADIGMS, NCT01892722 / 2011-005677-23: Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Checkmark PARADIGMS
Sep 2017 - Sep 2017: PARADIGMS
Recruiting
3
235
Europe, Canada, US, RoW
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Novartis Pharmaceuticals
Multiple Sclerosis
07/17
07/29
2020-004431-24: A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis Estudio para evaluar la eficacia, seguridad, farmacocinética y farmacodinamia de ponesimod frente a fingolimod durante 108 semanas de tratamiento en pacientes pediátricos, de 10 a <18 años, con esclerosis múltiple remitente recurrente.

Ongoing
3
212
Europe, RoW
Ponesimod, Fingolimod, JNJ-67896153/ACT-128800, Film-coated tablet, Capsule, Gilenya hard capsules
Janssen-Cilag International NV, Janssen Research & Development, LLC
Relapsing-remitting Multiple Sclerosis Esclerosis múltiple remitente recurrente., Chronic inflammatory disease attacking the CNS Enfermedad inflamatoria crónica que ataca al SNC., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT06408259: Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Not yet recruiting
3
194
US
Ozanimod, Fingolimod, Placebo
Celgene
Multiple Sclerosis, Relapsing-Remitting
04/31
07/36
ARTIOS, NCT04353492 / 2019-001341-40: An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Active, not recruiting
3
564
Europe, Canada, US, RoW
Ofatumumab, OMB157
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
04/25
04/25
Operetta 2, NCT05123703 / 2020-004128-41: A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis

Recruiting
3
171
Europe, Canada, US, RoW
Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
Hoffmann-La Roche, PPD
Relapsing-Remitting Multiple Sclerosis
07/25
09/29
NEOS, NCT04926818 / 2020-002700-39: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Recruiting
3
120
Europe, Canada, US, RoW
Fingolimod, FTY720, Ofatumumab, OMB157, Siponimod, BAF312, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Novartis Pharmaceuticals
Multiple Sclerosis (MS)
03/27
12/31

Download Options